239 related articles for article (PubMed ID: 27139485)
1. Dynamics of Mutations during Development of Resistance by Pseudomonas aeruginosa against Five Antibiotics.
Feng Y; Jonker MJ; Moustakas I; Brul S; Ter Kuile BH
Antimicrob Agents Chemother; 2016 Jul; 60(7):4229-36. PubMed ID: 27139485
[TBL] [Abstract][Full Text] [Related]
2.
Goodlet KJ; Nicolau DP; Nailor MD
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923865
[TBL] [Abstract][Full Text] [Related]
3. Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC.
Cabot G; Bruchmann S; Mulet X; Zamorano L; Moyà B; Juan C; Haussler S; Oliver A
Antimicrob Agents Chemother; 2014 Jun; 58(6):3091-9. PubMed ID: 24637685
[TBL] [Abstract][Full Text] [Related]
4. Activity of Ceftolozane-Tazobactam and Ceftazidime-Avibactam against Beta-Lactam-Resistant Pseudomonas aeruginosa Isolates.
Humphries RM; Hindler JA; Wong-Beringer A; Miller SA
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28993338
[TBL] [Abstract][Full Text] [Related]
5. Comparison of antibacterial activities of meropenem and six other antimicrobials against Pseudomonas aeruginosa isolates from North American studies and clinical trials.
Iaconis JP; Pitkin DH; Sheikh W; Nadler HL
Clin Infect Dis; 1997 Feb; 24 Suppl 2():S191-6. PubMed ID: 9126693
[TBL] [Abstract][Full Text] [Related]
6. Development of antibiotic resistance in Pseudomonas aeruginosa during two decades of antipseudomonal treatment at the Danish CF Center.
Ciofu O; Giwercman B; Pedersen SS; Høiby N
APMIS; 1994 Sep; 102(9):674-80. PubMed ID: 7946270
[TBL] [Abstract][Full Text] [Related]
7. [Antimicrobial susceptibility of phenotypically extended spectrum beta-lactamase producing Pseudomonas aeruginosa and Acinetobacter baumannii isolates].
Metan G; Zarakolu P; Hasçelik G; Akova M
Mikrobiyol Bul; 2006; 40(1-2):23-8. PubMed ID: 16775953
[TBL] [Abstract][Full Text] [Related]
8. [Susceptibility of 570 Pseudomonas aeruginosa strains to 11 antimicrobial agents and the mechanism of its resistance to fluoroquinolones].
Lei YC; Wang HB; Sun ZY; Shen ZY
Zhonghua Yi Xue Za Zhi; 2003 Mar; 83(5):403-7. PubMed ID: 12820918
[TBL] [Abstract][Full Text] [Related]
9. [Antibiotic susceptibility and occurrence of ESBL in Pseudomonas aeruginosa strains isolated from different clinical specimens].
Sacha PT; Jakoniuk P; Wieczorek P; Zalewska M; Leszczyńska K
Med Dosw Mikrobiol; 2004; 56(3):263-73. PubMed ID: 15773503
[TBL] [Abstract][Full Text] [Related]
10. Mutant prevention concentrations of levofloxacin alone and in combination with azithromycin, ceftazidime, colistin (Polymyxin E), meropenem, piperacillin-tazobactam, and tobramycin against Pseudomonas aeruginosa.
Zhanel GG; Mayer M; Laing N; Adam HJ
Antimicrob Agents Chemother; 2006 Jun; 50(6):2228-30. PubMed ID: 16723591
[TBL] [Abstract][Full Text] [Related]
11. Alterations in the GyrA and GyrB subunits of topoisomerase II and the ParC and ParE subunits of topoisomerase IV in ciprofloxacin-resistant clinical isolates of Pseudomonas aeruginosa.
Lee JK; Lee YS; Park YK; Kim BS
Int J Antimicrob Agents; 2005 Apr; 25(4):290-5. PubMed ID: 15784307
[TBL] [Abstract][Full Text] [Related]
12. Evolution of Pseudomonas aeruginosa Antimicrobial Resistance and Fitness under Low and High Mutation Rates.
Cabot G; Zamorano L; Moyà B; Juan C; Navas A; Blázquez J; Oliver A
Antimicrob Agents Chemother; 2016 Jan; 60(3):1767-78. PubMed ID: 26729493
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of combination therapy with cefepime, piperacillin-tazobactam, or meropenem with ciprofloxacin against multidrug-resistant Pseudomonas aeruginosa strains.
Erdem I; Kucukercan M; Ceran N
Chemotherapy; 2003 Dec; 49(6):294-7. PubMed ID: 14671429
[TBL] [Abstract][Full Text] [Related]
14. In vitro selection of resistance in Pseudomonas aeruginosa and Acinetobacter spp. by levofloxacin and ciprofloxacin alone and in combination with beta-lactams and amikacin.
Drago L; De Vecchi E; Nicola L; Tocalli L; Gismondo MR
J Antimicrob Chemother; 2005 Aug; 56(2):353-9. PubMed ID: 15967767
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of meropenem against ciprofloxacin-resistant enterobacteriaceae and Pseudomonas aeruginosa.
Garcia-Rodriguez JA; Blazquez AM; Fresnadillo MJ; Garcia Sanchez E; Garcia Sanchez JE; Trujillano Martin I
J Chemother; 1996 Oct; 8(5):358-64. PubMed ID: 8957715
[TBL] [Abstract][Full Text] [Related]
16. The role of gyrA and parC mutations in fluoroquinolones-resistant Pseudomonas aeruginosa isolates from Iran.
Nouri R; Ahangarzadeh Rezaee M; Hasani A; Aghazadeh M; Asgharzadeh M
Braz J Microbiol; 2016; 47(4):925-930. PubMed ID: 27522930
[TBL] [Abstract][Full Text] [Related]
17. Mature Pseudomonas aeruginosa biofilms prevail compared to young biofilms in the presence of ceftazidime.
Bowler LL; Zhanel GG; Ball TB; Saward LL
Antimicrob Agents Chemother; 2012 Sep; 56(9):4976-9. PubMed ID: 22777043
[TBL] [Abstract][Full Text] [Related]
18. Development of resistance and cross-resistance in Pseudomonas aeruginosa exposed to subinhibitory antibiotic concentrations.
Wu YL; Scott EM; Po AL; Tariq VN
APMIS; 1999 Jun; 107(6):585-92. PubMed ID: 10379686
[TBL] [Abstract][Full Text] [Related]
19. gyrA and parC mutations in quinolone-resistant clinical isolates of Pseudomonas aeruginosa from Nini Hospital in north Lebanon.
Salma R; Dabboussi F; Kassaa I; Khudary R; Hamze M
J Infect Chemother; 2013 Feb; 19(1):77-81. PubMed ID: 22821356
[TBL] [Abstract][Full Text] [Related]
20. In vivo evolution of resistance of Pseudomonas aeruginosa strains isolated from patients admitted to an intensive care unit: mechanisms of resistance and antimicrobial exposure.
Solé M; Fàbrega A; Cobos-Trigueros N; Zamorano L; Ferrer-Navarro M; Ballesté-Delpierre C; Reustle A; Castro P; Nicolás JM; Oliver A; Martínez JA; Vila J
J Antimicrob Chemother; 2015 Nov; 70(11):3004-13. PubMed ID: 26260130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
